Manage drug-induced photosensitivity by preventing, discontinuing offending agents and/or treating when necessary
Tóm tắt
Photosensitive drug eruptions occur after exposure to a photosensitizing drug and either ultraviolet or visible radiation. Numerous medications from a variety of drug classes have been associated with photoallergic and phototoxic drug reactions. Educating patients about the potential risk of drug-induced photosensitivity and appropriate preventive measures is the mainstay of management. Discontinuation of the offending agent is important once a photosensitive reaction is confirmed; photosensitivity usually resolves shortly after discontinuation of the offending drug, and short-time treatment with topical or systemic corticosteroids may be of benefit in some affected patients. Long-term surveillance may be indicated in some cases due to the risk of incident malignancies.
Tài liệu tham khảo
Blakely KM, Drucker AM, Rosen CF. Drug-induced photosensitivity-an update: culprit drugs, prevention and management. Drug Saf. 2019;42(7):827–47.
Kim WB, Shelley AJ, Novice K, et al. Drug-induced phototoxicity: a systematic review. J Am Acad Dermatol. 2018;79(6):1069–75.
Lowe NJ, Fakouhi TD, Stern RS, et al. Photoreactions with a fluoroquinolone antimicrobial: evening versus morning dosing. Clin Pharmacol Ther. 1994;56(5):587–91.
Collins P, Ferguson J. Narrow-band UVB (TL-01) phototherapy: an effective preventative treatment for the photodermatoses. Br J Dermatol. 1995;132(6):956–63.
Hamanaka H, Mizutani H, Shimizu M. Sparfloxacin-induced photosensitivity and the occurrence of a lichenoid tissue reaction after prolonged exposure. J Am Acad Dermatol. 1998;38(6 Pt 1):945–9.
Li WQ, Drucker AM, Cho E, et al. Tetracycline use and risk of incident skin cancer: a prospective study. Br J Cancer. 2018;118(2):294–8.
Siiskonen SJ, Koomen ER, Visser LE, et al. Exposure to phototoxic NSAIDs and quinolones is associated with an increased risk of melanoma. Eur J Clin Pharmacol. 2013;69(7):1437–44.
Kolaitis NA, Duffy E, Zhang A, et al. Voriconazole increases the risk for cutaneous squamous cell carcinoma after lung transplantation. Transpl Int. 2017;30(1):41–8.
Miller DD, Cowen EW, Nguyen JC, et al. Melanoma associated with long-term voriconazole therapy: a new manifestation of chronic photosensitivity. Arch Dermatol. 2010;146(3):300–4.
Williams K, Mansh M, Chin-Hong P, et al. Voriconazole-associated cutaneous malignancy: a literature review on photocarcinogenesis in organ transplant recipients. Clin Infect Dis. 2014;58(7):997–1002.
Li AW, Lalor LE, Bellodi Schmidt F, et al. A pediatric case of squamous cell cancer in situ in the setting of sclerodermatous graft-versus-host disease and voriconazole treatment. Pediatr Dermatol. 2018;35(3):e165–9.
Wong JY, Kuzel P, Mullen J, et al. Cutaneous squamous cell carcinoma in two pediatric lung transplant patients on prolonged voriconazole treatment. Pediatr Transplant. 2014;18(6):E200–7.
Jensen AO, Thomsen HF, Engebjerg MC, et al. Use of photosensitising diuretics and risk of skin cancer: a population-based case-control study. Br J Cancer. 2008;99(9):1522–8.
Gandini S, Palli D, Spadola G, et al. Anti-hypertensive drugs and skin cancer risk: a review of the literature and meta-analysis. Crit Rev Oncol Hematol. 2018;122:1–9.